NCT04414475

A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

A Phase 2b, Open-label, Multi-arm Clinical Trial of Selinexor Plus Low-dose Dexamethasone (Sd) in Patients With Penta-refractory Multiple Myeloma or Selinexor and Bortezomib Plus Low-dose Dexamethasone (SVd) in Patients With Triple-class Refractory Multiple Myeloma

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 127 (estimated)
• Sponsor: Karyopharm Therapeutics Inc · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the efficacy, antitumor activity, safety and tolerability of selinexor plus low-dose dexamethasone in participants with penta-refractory multiple myeloma or selinexor and bortezomib plus low-dose dexamethasone in participants with triple-class refractory multiple myeloma.

Conditions

• Multiple Myeloma, Refractory

Interventions

Type	Name	Description
DRUG	Selinexor	Participants will receive Selinexor oral tablets.
DRUG	Dexamethasone	Participants will receive Dexamethasone oral tablets.
DRUG	Bortezomib	Participants will receive Bortezomib SC injection.

Timeline

• Start date: 2020-07-01
• Primary completion: 2028-01-01
• Completion: 2028-01-01
• First posted: 2020-06-04
• Last updated: 2026-02-02

Locations

16 sites across 2 countries: Greece, Israel

Regulatory

• FDA-regulated drug study